2021
DOI: 10.1186/s12931-021-01777-x
|View full text |Cite
|
Sign up to set email alerts
|

Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis

Abstract: Background Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been recommended for patients with COPD who have severe symptoms and a history of exacerbations because it reduces the exacerbations. In addition, a reducing effect on mortality has been shown by this treatment. However, the evidence is mainly based on one large randomized controlled trial IMPACT study, and it remains unclear w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 28 publications
(16 citation statements)
references
References 44 publications
0
16
0
Order By: Relevance
“…Third, our data analyzed the effect of eosinophil for choosing triple therapy or other therapies, which was not discussed in other meta-analysis. [42,43]…”
Section: Discussionmentioning
confidence: 99%
“…Third, our data analyzed the effect of eosinophil for choosing triple therapy or other therapies, which was not discussed in other meta-analysis. [42,43]…”
Section: Discussionmentioning
confidence: 99%
“…The results of clinical trials of triple therapy in a single inhalation device versus dual or single therapies have been extensively reported in numerous studies, not only in the original clinical trials, but also in pooled analyses of clinical trials, post-hoc analyses, systematic reviews and narrative reviews [30][31][32][33][34] . Advantages in lung function and patient-reported outcomes have been reported in trials comparing single-inhaler triple therapies to multiple treatments in symptomatic patients with moderate to very severe airflow limitation and increased risk of exacerbations.…”
Section: What Does Triple Therapy In Copd Provide Versus Single or Du...mentioning
confidence: 99%
“…In contrast, ICS could be associated with the local adverse events - oral candidiasis and dysphonia, and systemic complications, such as diabetes mellitus, osteoporotic fractures, glaucoma, and mycobacterial infection [7] , [8] , [9] , [10] , [11] , [12] . In addition, solid evidences have demonstrated a significant association between the use of ICS and the increasing risk of pneumonia [12] , [13] , [14] , which implied this serious concern about the safety issue of ICS prescription in those patients. During COVID-19 pandemic, it is important to know the impact of ICS on the risk of SARS-CoV-2 infections or COVID-19 pneumonia.…”
Section: Introductionmentioning
confidence: 99%